MedTrace Logo

Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients

NCT04394091 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-05-19

No results posted yet for this study

Summary

NPC Patients receiving IMRT treatment will receive a dedicated FDG PET/CT and high-sensitivity PET/CT protocol simultaneously in the follow-up of Locally Advanced Nasopharyngeal Carcinoma. Hence we establish this prospective cohort study.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DEVICE

ultrasensitive PET CT

A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. Its total-body coverage and exceptional sensitivity provide opportunities for innovative studies of physiology, biochemistry, and pharmacology.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Haiqiang Mai, Dr · Sun Yat-sen University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-20
Primary Completion
2020-12-20
Completion
2020-12-20
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04394091 on ClinicalTrials.gov